本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SHANGHAI, Jan. 26, 2026 /PRNewswire/ -- Moyom Biotechnology recently announced a strategic partnership with WPP Group, one of the world's leading global communications and creative networks. The partnership is centered on the "Poetics of Time" brand framework and will focus on the long-term evolution of Aphranel's global brand communications. Moyom Biotechnology Announces Strategic Partnership with WPP Group Headquartered in London, WPP Group operates in more than 100 countries worldwide, integrating capabilities across creative, media, public relations, digital, consulting, and artificial intelligence. Through the partnership, WPP will draw on its global resources and integrated expertise to help Aphranel establish a clear, consistent, and internationally relevant, market-ready brand narrative, while communicating the values and the underlying scientific and clinical approach behind Poetics of Time to a broader professional audience. Aphranel is a core brand of Moyom Biotechnology, positioned as the first CaHA-based regenerative injectable to receive regulatory approval in China. The brand is defined by an approach centered on a return to core medical principles, emphasizing structural support and long-term biological processes aligned with the natural rhythm of time. "Poetics of Time" reflects Aphranel's belief that aesthetic medicine should move beyond the notion of resisting aging, and instead focus on respecting anatomy, material science, and long-term clinical value. The partnership with WPP represents a key step in strengthening the brand's global expression at the intersection of regenerative science and a clinically grounded, time-based medical philosophy. Moyom Biotechnology said that it will continue working with WPP to expand the international reach of Aphranel and further build long-term brand trust and consistency across global markets. About Aphranel Aphranel is a core brand of Moyom Biotechnology, focused on professional medical aesthetics applications for clinical use. The brand specializes in facial injectables and regenerative materials, driven by science-based development and a sustained commitment to long-term clinical value. About Moyom Biotechnology Moyom Biotechnology is a medical technology company dedicated to regenerative materials and professional medical aesthetics, with a focus on science-based solutions and sustainable innovation in healthcare delivery. About WPP WPP is the world's largest advertising and marketing services group, providing integrated brand, media, public relations, data, and technology solutions worldwide.
PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, scheduled for January 14, 2026, at the San Francisco Marriott Marquis, with both in-person and virtual attendance options available. Now in its fifth year, GenScript Biotech Global Forum has become a convening platform to push the boundaries of what's possible for the global biotech ecosystem. Held alongside the annual J.P. Morgan Healthcare Conference week, the Forum brings together the scientists, innovators, investors and decision-makers to discuss the future of biotechnology – where discovery, computation and therapeutic development converge to turn scientific possibilities into patient impact. Under the theme 'Scripting Possibilities', this year's Forum will explore how transformative advancements, computational revolutions and emerging technologies redefine what is possible in cell and gene therapies (CGTs) and next-generation biotherapeutics. Attendees will engage in forward-looking discussions on the technologies and collaborations shaping next-generation biotherapeutics and accelerating the path from idea to impact. "The Global Forum has become a central gathering point for leaders driving progress across the biotech ecosystem," said Sherry Shao, CEO, GenScript Biotech Corp. "We are proud to bring this community together in San Francisco once again. Our mission is to empower researchers and companies end-to-end – with integrated technologies, platforms and expertise – from discovery to development and manufacturing through our Life Science Group and ProBio businesses. GenScript is confidently expanding its role in the industry to turn bold scientific ideas into real therapeutic impact and to accelerate the delivery of these innovations to patients worldwide." Two Visionaries Defining the Next Chapter in BiotechThe 5th Annual Biotech Global Forum will feature two globally recognized keynote speakers whose work is redefining the boundaries of science, computation, and therapeutic innovation: David Baker, PhD, Director, Institute for Protein Design; Professor of Biochemistry, University of Washington; Investigator, Howard Hughes Medical Institute; Nobel Laureate in Chemistry (2024). Dr. Baker is the pioneer of computational protein design, creating new molecules and therapeutic modalities once thought impossible and fundamentally redefining how medicines can be engineered. Eric Horvitz, PhD, MD, Chief Scientific Officer, Microsoft. Dr. Horvitz is a trailblazer in artificial intelligence and responsible AI, driving advancements that are influencing how computation accelerates biomedical research, drug development and clinical decision-making at global scale. Together, these leaders represent the convergence of biology and intelligence – where molecules are designed with algorithms and insight is amplified through AI. Forum Highlights: Keynote & Fireside Conversation: A forward-looking discussion on computational protein design, AI and the future architecture of therapeutic innovation. Insight-Driven Panel Sessions: Exploring the next frontier in cell and gene therapy, AI-enabled drug discovery and the global forces shaping biotech's evolution. Technology Showcase: Featuring GenScript's next-generation Dark Lab and GenGenius+ automation platform, demonstrating how AI and automation are transforming laboratory workflows. Advanced Therapy Spotlight: Perspectives on translating CGT innovation into scalable, clinical-ready solutions, informed by GenScript's end-to-end capabilities, including ProBio's advanced biologics and cell and gene therapy manufacturing expertise. High-Impact Networking: Connecting scientists, biotech leaders, investors and technology partners to spark collaboration and unlock new opportunities throughout the program and evening reception. "Biotechnology is at an inflection point – where speed, precision and collaboration are no longer optional," said Ray Chen, PhD, President, GenScript Life Science Group. "The Global Forum is designed to bring together the leaders scripting what comes next, and to explore ways of pushing the boundaries of what's seemingly impossible. This year's program reflects a powerful convergence – discovery science, computational intelligence and therapeutic development coming together to script what's possible next. When these forces align, scientific discoveries move faster, scale smarter and reach patients sooner." Registration for the GenScript Biotech Global Forum is now open. For more information and to register, please visit GenScript's official website. About GenScript Biotech CorporationFounded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, GenScript supports customers across the full innovation lifecycle - from early discovery and automation-driven research to advanced biologics and manufacturing - including through its ProBio business. GenScript has a team of over 5,700 employees and has served more than 200,000 customers across over 100 countries and regions. Learn more here: https://www.genscript.com. Media ContactStefanie TuckCG Lifestuck@cglife.com
TAICHUNG, Dec. 9, 2025 /PRNewswire/ -- Backed by New Medical Association Certification, Insumate® Becomes the Only Bitter Melon Peptide Globally Recognized by FDA-NDI, SNQ, and the Taiwan Complementary Medicine Society (TCMS). As global demand for scientifically validated metabolic health ingredients continues to rise, Greenyn Biotechnology Co., Ltd., a publicly listed biotechnology company in Taiwan, announced today that its flagship ingredient Insumate® mcIRBP-19 Bitter Melon Peptide has been awarded the "Excellent Product Quality Certification" by the Taiwan Complementary Medicine Society (TCMS). This recognition positions Insumate® as the only bitter melon peptide ingredient to have simultaneously obtained: Certification from the Taiwan Complementary Medicine Society (TCMS) U.S. FDA New Dietary Ingredient (NDI) approval Symbol of National Quality (SNQ) This combination of recognitions is currently unmatched among bitter-melon–derived functional ingredients worldwide. Choose products with national and international certifications to minimize health risks from excessive or unknown ingredients from the source. According to Greenyn Biotechnology's General Manager and R&D lead Dr. Pang-Kuei Hsu, this certification confirms that the ingredient has passed stringent reviews covering raw materials, manufacturing, scientific validation, and clinical research—establishing it as a trusted reference for medical professionals selecting nutritional support ingredients. Greenyn expects the new certification to further enhance the medical community's confidence in clinically supported functional ingredients and accelerate the company's expansion across the Asia-Pacific region. Growing Demand for Metabolic Health Solutions: Greenyn Sets a New Benchmark with Evidence-Based Bitter Melon Peptide Research Recent data from the International Diabetes Federation (IDF) highlights the increasing global need for metabolic health solutions. As of 2024, 589 million adults worldwide—approximately 1 in 9 people—are living with diabetes, a number projected to reach 853 million by 2050. Over 12 Years of Research, Three Major Certifications: Insumate® mcIRBP-19 Builds Strong Trust Among Professionals and Consumers Greenyn spent over a decade collaborating with medical schools and biomedical research institutions in Taiwan to develop Insumate®. Using low-temperature supercritical extraction, the team successfully isolated the bioactive mcIRBP-19 peptide, a precisely sequenced small-molecule peptide extracted from bitter melon. This solvent-free process preserves peptide integrity and bioactivity, setting it apart from conventional solvent extraction methods that produce undefined polypeptide mixtures. Patented 19-Peptide Directly Interacts with Insulin Receptors to Support Glucose Control Research conducted by Greenyn shows that mcIRBP-19 directly interacts with insulin receptors through a unique binding site, activating downstream signaling pathways that support efficient glucose utilization. Clinical studies in Taiwan demonstrated that consuming mcIRBP-19 for 12 weeks resulted in: around 14% reduction in fasting blood glucose over 22% reduction in triglycerides significant improvement in HbA1c For sub-health populations, including aging individuals or those experiencing metabolic slowdown, international studies have shown that high doses of bitter melon components help maintain stable blood glucose levels and significantly improve HbA1c and triglycerides in older subgroups. To date, more than seven SCI-indexed papers and three large-scale clinical trials involving over 200 subjects have validated its efficacy. Dr. Tao-Ming Chen, President of the Taiwan Complementary Medicine Society (TCMS), emphasized: "Products certified by the Taiwan Complementary Medicine Society have met strict standards in scientific validation, clinical evidence, and quality management, offering healthcare professionals a trustworthy reference for supportive nutrition. In recent years, bitter melon has become one of the most studied ingredients for metabolic and blood glucose support. Many products on the market claim to contain bitter melon; however, only by choosing patented formulas that carry the Society's certification can consumers truly support daily metabolic management and maintain better overall health." This certification establishes Insumate® as a clinically supported functional ingredient suitable for long-term metabolic health management. Expanding Globally: Strengthening International Presence According to Fortune Business Insights, the global nutraceutical market is expected to grow from USD 458.5 billion in 2024 to USD 986.8 billion by 2032, with a CAGR of 10.18%. The Asia-Pacific region is projected to exceed 30% of global market share by 2026, driven by rising demand for science-backed, clinically effective functional ingredients. Greenyn has established multiple international collaborations and continues strengthening its presence across the Asia-Pacific region and global markets. Insumate® has now expanded into more than ten countries, achieving commercial launches and demonstrating strong market acceptance across diverse regions. The company will continue deepening and broadening its global partnerships while advancing regulatory pathways across Asia, the U.S., and the EU to support long-term international compliance. Driving Taiwan's Biotech Industry from Manufacturing to Innovation Dr. Hsu emphasized that Greenyn has developed multiple patented ingredients including Insumate® mcIRBP-19 Bitter Melon Peptide, Antromax® Antrodia cinnamomea mycelia, and other proprietary innovations. The company holds over 100 international patents, more than 30 global invention awards, and is certified under HACCP, ISO 22000, FSSC 22000, and Halal. Greenyn provides end-to-end services from raw material development to formulation design and full ODM/OEM manufacturing. Greenyn aims to accelerate global collaborations and become the leading provider of scientifically validated functional ingredients across the Asia-Pacific and beyond.
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 9, 2025 /PRNewswire/ -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical. The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio's infectious disease diagnostics portfolio and supports public health efforts in responding to emerging outbreaks. In parallel, Anbio is advancing the boundaries of decentralized molecular diagnostics with the launch of its new AP-100 Ultra-Fast PCR system, designed to bring laboratory-grade testing capabilities directly to the point of care. "Outbreaks demand speed. The AP-100 collapses hours of traditional PCR into minutes, without compromising accuracy," said Michael Lau, CEO of Anbio Biotechnology. The AP-100 utilizes an advanced microfluidic thermal cycling system combined with high-efficiency enzymatic amplification chemistry, enabling direct processing of swab samples without the need for nucleic acid extraction. Its integrated design streamlines sample-to-result workflows, making it well-suited for deployment in both centralized laboratories and decentralized, point-of-care environments. Key highlights: 15-minute PCR results from raw sample to answer Extraction-free workflow with no hazardous reagents Compact 668g device for mobile or near-patient testing Broad pathogen coverage, including COVID-19, Flu A/B, RSV, MP, and ADV Lab-comparable accuracy validated against mainstream PCR platforms While initially focused on respiratory infections, the AP-100 is designed as a flexible molecular platform. In line with its global infectious disease strategy, Anbio is expanding the assay portfolio to include tests for tuberculosis (TB) and human papillomavirus (HPV), extending its role from rapid outbreak response to sustained disease management. "Whether it's vector-borne fevers or respiratory pandemics, we believe diagnostics should move as fast as the threat," Lau added. With its combination of speed, mobility, and lab-grade precision, Anbio's new-generation POCT PCR system strengthens healthcare capacity in both well-resourced and resource-limited settings, advancing global preparedness for infectious disease threats. About Anbio Biotechnology Anbio Biotechnology is a globally oriented in vitro diagnostics (IVD) company providing a broad range of solutions, including immunofluorescence, dry chemistry, chemiluminescence, molecular diagnostics, rapid testing and veterinary diagnostics. With operations across multiple regions, the company works to enhance the availability of reliable and timely diagnostics, supporting better decision-making in healthcare settings worldwide. For more information about Anbio Biotechnology, follow us for the latest news and updates.
PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a future-forward identity designed to match the speed, complexity, and promise of modern biotechnology. The brand relaunch reflects GenScript's ambition to become the most trusted partner for researchers worldwide—delivering scientific accelerations from discovery to manufacturing with speed, precision, and purpose. The new platform, visual identity, and tagline roll out globally today, on GenScript's 23rd birthday, across every region and touchpoint. "This is the moment to share our story of making the impossible possible with the world —driven by unwavering customer focus, bold scientific innovation, and a relentless sense of purpose," said Sherry Shao, Rotating CEO of GenScript Biotech Corporation. "With heartfelt customer testimonials as demonstration, GenScript is entering its next chapter with unity, ambition, and clarity of mission. We remain steadfast in our vision to become a great company that scripts the future of life sciences - transforming bold scientific possibilities into realities that heal and sustain our world. Simultaneously, we are expanding our global footprint—especially in the U.S. and Singapore—through major investments in operations and production capacity to meet the accelerating demand." "Scripting Possibilities is more than a tagline—it captures the mindset of our people and the promise we make to every customer," said Ray Chen, President of GenScript Life Science Group. "This evolution unites our global footprint, deepens trust, and reaffirms our commitment to making people and nature healthier through biotechnology." The new identity was developed under the leadership of Aylin Kosova Bilgin, GenScript's newly appointed Chief Marketing Officer, who brings in global marketing leadership to accelerate the Company's transformation into a high-performing, data-led, and customer-obsessed organization. She is reshaping GenScript's internal and external marketing capabilities to drive growth, relevance, and global brand strength, and is now spearheading GenScript's marketing transformation to reflect its science, scale, and soul. "GenScript wasn't born as a biotech leader—it was built," she said. "We're not just an industry leader. We're a force in the future of life sciences, pushing the boundaries of what's seemingly impossible." The refreshed brand—co-created with global designers across 17 countries—will come to life through: - Human-led storytelling featuring GenScript's internal heroes - A global customer celebration with omni-channel testimonials and promotional campaign - A digital-first brand experience designed to inspire scientists and collaborators - A new company anthem and original single launching globally - Expanded via collaborations and timely funding through the GenScript Research Grant initiative Key facts: - New tagline: Scripting Possibilities - New visual identity: Future-forward, digital-first, emotionally resonant - Strategic repositioning: GenScript as a global co-author of scientific breakthroughs - Aligned with market needs: Responding to global trust and competition dynamics - Over 200,000 customers served across 100+ countries - $110M+ U.S. investment in molecular biology, protein manufacturing and CGT - 5,500+ employees globally - Accelerated growth in U.S., EU, and Asia-Pacific regions At a time when biotechnology is advancing faster than ever—and trust, transparency, and precision are in high demand—GenScript's brand elevation is a confident signal to scientists, investors, and stakeholders worldwide. The future of biotechnology is not written yet. GenScript proves that from bench to bedside, GenScript is ready to script what's next—side by side with scientists, for the world. About GenScript Biotech Corporation Founded in 2002 in New Jersey, GenScript Biotech Corporation accelerates innovation in biotech and healthcare by providing researchers and companies with the building blocks needed to develop groundbreaking treatments and products. Guided by its mission to Make People and Nature Healthier Through Biotechnology, and its role as a trusted global leader, GenScript has a team of over 5,500 employees and has served more than 200,000 customers acrossover100 countries and regions. Learn more here: https://www.genscript.com
JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its financial results for the fiscal year ended December 31, 2024. Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, "Fiscal year 2024 was a transformational year for us, marked by strategic decisions and tough yet necessary shifts, as we navigated significant market adjustments and proactively diversified our customer base in pursuit of long-term growth. Amid global uncertainties and challenging domestic market conditions, we made the deliberate decision to reduce sales of swine vaccines, primarily to mitigate concentration risk from our largest customers. We believe this will lead to a healthier and more balanced customer portfolio to better support our strategic diversification. Meanwhile, we have maintained our research and development ("R&D") investments, recognizing that innovation is key to sustainable and long-term growth, even amid current headwinds. Over the past year, we made progress in expanding into China's fast-growing pet vaccine market, having completed clinical trials for two vaccines targeting cats and dogs. We see this as a high-potential segment and expect it to become a key focus moving forward. Additionally, we were honored to receive two Category I New Veterinary Drug Certificates from the Ministry of Agriculture and Rural Affairs for two vaccines jointly developed by us and other institutions, which is a strong testament to our R&D capabilities. Mr. Aiden Han, co-chief executive officer of Zhengye, added, "With our successful Nasdaq listing, global market expansion has become a central component of our long-term vision to become a world-leading, trusted manufacturer of veterinary vaccines. Exploring international sales opportunities and expanding our global distribution network will be a strategic priority in the years ahead. Though these transitional measures may bring noticeable short-term effects, we believe the long-term benefits will be enduring and substantial. We are building a more resilient and adaptable foundation to support our growth ambitions. Our unwavering commitment to developing safe and innovative products and consistently delivering high quality will continue to be the cornerstone of long-term value creation for our stakeholders." Fiscal Year 2024 Financial Summary Net revenues were RMB186.4 million (US$25.5 million) in fiscal year 2024, compared to RMB211.7 million in fiscal year 2023. Gross profit was RMB91.3 million (US$12.5 million) in fiscal year 2024, compared to RMB117.5 million in fiscal year 2023. Gross profit margin was 49.0% in fiscal year 2024, compared to 55.5% in fiscal year 2023. Total operating expenses were RMB74.9 million (US$10.3 million) in fiscal year 2024, increased from RMB72.5 million in fiscal year 2023. Net income was RMB13.5 million (US$1.8 million) in fiscal year 2024, compared to RMB37.5 million in fiscal year 2023. Basic and diluted earnings per share were RMB0.25 (US$0.03) in fiscal year 2024, compared to RMB0.69 in fiscal year 2023. Fiscal Year 2024 Financial Results Net Revenues Net revenues were RMB186.4 million (US$25.5 million) in fiscal year 2024, representing a decrease of 12.0% from RMB211.7 million in fiscal year 2023. The decrease was primarily due to the veterinary vaccine market adjustments and the reduced sales of swine vaccines following the Company's strategic realignment of sales practices aimed at diversifying the customer base and reducing concentration risk. For the years ended December 31, 2023 2024 RMB % RMB US$ % (in thousands, except for percentages) Revenues Swine vaccines 188,919 89.3 157,789 21,617 84.7 Poultry vaccines 15,430 7.3 15,506 2,124 8.3 Other vaccines 7,302 3.4 13,061 1,790 7.0 Total revenues 211,651 100 186,356 25,531 100 Revenue from sales of swine vaccines was RMB157.8 million (US$21.6 million) in fiscal year 2024, decreased from RMB188.9 million in fiscal year 2023. The decrease was a result of the control of sales to Zhengye's operating entity's largest customer. Revenue from sales of poultry vaccines was RMB15.5 million (US$2.1 million) in fiscal year 2024, increased from RMB15.4 million in fiscal year 2023. There was no significant change in revenue from sales of poultry vaccines and the difference was caused by normal demand fluctuation. Revenue from sales of other vaccines was RMB13.1 million (US$1.8 million) in fiscal year 2024, increased from RMB7.3 million in fiscal year 2023. The increase in sales of other vaccines was caused by the increased sales of the vaccines for sheep. Cost of Revenues Cost of revenues was RMB95.1 million (US$13.0 million) in fiscal year 2024, representing an increase of 1.0% from RMB94.1 million in fiscal year 2023. The increase was mainly due to the increase in the cost of poultry vaccines. Gross Profit Gross profit was RMB91.3 million (US$12.5 million) in fiscal year 2024, decreased from RMB117.5 million in fiscal year 2023. Gross profit margin was 49.0% in fiscal year 2024, decreased from 55.5% in fiscal year 2023. The decrease was mainly due to the lower sales price and unchanged fixed cost. Operating Expenses Total operating expenses were RMB74.9 million (US$10.3 million) in fiscal year 2024, increased from RMB72.5 million in fiscal year 2023. Sales and marketing expenses were RMB41.3 million (US$5.7 million) in fiscal year 2024, increased from RMB40.7 million in fiscal year 2023. The increase in sales and marketing expenses mainly resulted from an increase in payroll for sales staffs, marketing promotion expenses and entertainment, partially offset by a decrease in travel expenses and advertising expenses. General and administrative expenses were RMB22.6 million (US$3.1 million) in fiscal year 2024, decreased from RMB23.6 million in fiscal year 2023. The decrease in administrative expenses is attributed to the reduction in employee compensation and decrease in depreciation and amortization. Research and development expenses were RMB12.8 million (US$1.8 million) in fiscal year 2024, increased from RMB11.9 million in fiscal year 2023. The increase in research and development expenses mainly resulted from an increase in material expenses. Net Income Net income was RMB13.5 million (US$1.8 million) in fiscal year 2024, compared to RMB37.5 million in fiscal year 2023. Basic and Diluted Earnings per Share Basic and diluted earnings per share were RMB0.25 (US$0.03) in fiscal year 2024, compared to RMB0.69 in fiscal year 2023. Financial Condition As of December 31, 2024, the Company had cash of RMB18.6 million (US$2.5 million), compared to RMB15.1 million as of December 31, 2023. Net cash provided by operating activities was RMB41.0 million (US$5.6 million) in fiscal year 2024, compared to RMB48.2 million in fiscal year 2023. Net cash used in investing activities was RMB27.7 million (US$3.8 million) in fiscal year 2024, compared to RMB11.8 million in fiscal year 2023. Net cash used in financing activities was RMB22.1 million (US$3.0 million) in fiscal year 2024, compared to RMB19.0 million in fiscal year 2023. Exchange Rate Information This announcement contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations of Renminbi ("RMB") into U.S. dollars ("US$") were made at RMB7.2993 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on December 31, 2024. Recent Development On January 8, 2025, the Company closed its initial public offering (the "Offering"). We issued and sold an aggregate of 1,500,000 ordinary shares at a public offering price of $4.00 per ordinary share. On January 14, 2025, Kingswood Capital Partners, LLC, as the representative of the underwriters of the Offering, exercised their over-allotment option in full to purchase an additional 225,000 ordinary shares at the public offering price of $4.00 per share. The total gross proceeds received from the Offering, including proceeds from the exercise of the over-allotment option, were $6.9 million, before deducting underwriting discounts and other related expenses. The Company's ordinary shares commenced trading on the Nasdaq Capital Market on January 7, 2025, under the ticker symbol "ZYBT." On February 25, 2025, the Ministry of Agriculture and Rural Affairs ("the Ministry") approved the Live Vaccine for Mycoplasma bovis (Strain HB150) (2025 No.11) as a Category I New Veterinary Drug, which was jointly developed by the Company, Huazhong Agricultural University and other institutions. On March 21, 2025, the Ministry announced the approval (2025 No.18) of another Category I New Veterinary Drug — a Pentavalent Inactivated Vaccine for poultry diseases including Newcastle Disease, Infectious Bronchitis, Avian Influenza (H9), Infectious Bursal Disease, and Avian Adenovirus (Group I, Serotype 4), which was jointly developed by the Company, Pulike Biological Engineering, Inc. and other institutions. Both of these veterinary vaccines have obtained the national Category I Veterinary Drug Registration Certificate ("Category I Certificate"), marking a major breakthrough for the Company in the field of animal vaccine R&D. Category I Certificates are granted to biological products that demonstrate significant innovation and are being developed for the first time, either domestically or internationally, without prior market entry. Compared to Category II and III New Veterinary Drugs, Category I New Veterinary Drugs enjoy the longest monitoring period of up to five years. During this period, no other companies, except for the original applicants, are permitted to produce or import the drugs. This exclusivity creates a strong technological entry barrier and is expected to generate substantial economic returns while enhancing the Company's industry influence. About Zhengye Biotechnology Holding Limited Through Jilin Zhengye Biological Products Co., Ltd., the Company's operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 46 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 28 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The operating entity has three GMP veterinary vaccine production floors, including 13 GMP vaccine production lines, one quality examination center, and one animal facility for vaccine development. The operating entity has 49 employees who have over a decade of experience in the veterinary vaccine industry. For more information, please visit the Company's website: http://ir.jlzybio.com. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. For more information, please contact: Zhengye Biotechnology Holding Limited Investor Relations DepartmentEmail: ir@jlzybio.com Ascent Investor Relations LLCTina XiaoPhone: +1-646-932-7242Email: investors@ascent-ir.com ZHENGYE BIOTECHNOLOGY HOLDING LIMITED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of RMB and US$, except for number of shares) As of December 31, 2023 2024 RMB RMB US$ ASSETS Current assets: Cash 15,073 18,604 2,549 Restricted Cash 12,113 2 — Short-term investments 1,224 1,433 197 Notes receivable, net 23,215 25,592 3,506 Accounts receivable, net 74,166 59,563 8,160 Advance to suppliers 3,110 10,788 1,478 Inventories, net 58,300 58,220 7,977 Other receivables, net 1,302 2,626 360 Other receivable-a related party 738 738 101 Total current assets 189,241 177,566 24,328 Non-current assets: Property, plant and equipment, net 263,248 255,164 34,957 Land use rights, net 8,187 7,930 1,087 Intangible assets, net 16,297 14,850 2,034 Long-term prepayments 6,504 18,698 2,562 Deferred IPO expenses 4,497 8,048 1,103 Net deferred tax assets 11,914 10,991 1,506 Total non-current assets 310,647 315,681 43,249 Total assets 499,888 493,247 67,577 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Short-term loans 79,860 74,443 10,199 Current maturities of long term loans — 7,190 985 Accounts payable 45,659 42,960 5,885 Contract liabilities 3,885 3,485 477 Taxes payable 2,295 2,066 283 Dividends payable 15,652 — — Amount due to related parties — 146 20 Accrued expenses and other liabilities 2,882 5,617 769 Total current liabilities 150,233 135,907 18,618 Non-current liabilities: Long-term loans 9,990 4,800 658 Other payables – non-current 393 — — Total non-current liabilities 10,383 4,800 658 Total liabilities 160,616 140,707 19,276 Commitments and contingencies Shareholders' equity: Ordinary shares (US$0.000025 par value; 2,000,000,000 shares authorized; 45,666,376 shares issued and outstanding as of December 31, 2023 and 2024)* 8 8 1 Additional paid-in capital 203,150 203,150 27,832 Statutory reserves 31,311 32,647 4,473 Retained earnings 38,381 48,151 6,597 Accumulated other comprehensive income — 3 — Total Zhengye Biotechnology Holding Limited's shareholders' equity 272,850 283,959 38,903 Noncontrolling interests 66,422 68,581 9,398 Total equity 339,272 352,540 48,301 Total liabilities and equity 499,888 493,247 67,577 * Retroactively adjusted for effect of a 4-for-1 forward split on June 6, 2024. ZHENGYE BIOTECHNOLOGY HOLDING LIMITED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Amounts in thousands of RMB and US$, except for number of shares and per share data) For the years ended December 31, 2022 2023 2024 RMB RMB RMB USD Net revenues 260,269 211,651 186,356 25,531 Cost of revenues (112,390) (94,143) (95,061) (13,023) Gross profit 147,879 117,508 91,295 12,508 Sales and marketing expenses (34,565) (40,743) (41,269) (5,654) General and administrative expenses (24,321) (23,592) (22,575) (3,093) Research and development expenses (13,424) (11,901) (12,794) (1,753) Reversal (allowance) for credit losses (9,735) 3,714 1,782 244 Total operating expenses (82,045) (72,522) (74,856) (10,256) Operating income 65,834 44,986 16,439 2,252 Other income (expenses): Other income 650 433 692 95 Other expenses (100) (199) (337) (45) Interest income 114 312 231 32 Interest expense (2,839) (4,423) (4,043) (554) Unrealized foreign exchange gain — — 679 93 Government subsidy 255 2,653 733 100 Total other expenses, net (1,920) (1,224) (2,045) (279) Income before income taxes 63,914 43,762 14,394 1,973 Income tax expenses (8,172) (6,253) (924) (127) Net income 55,742 37,509 13,470 1,846 Net income attributable to noncontrolling interests (9,007) (6,052) (2,159) (296) Net income attributable to the Zhengye Biotechnology Holding Limited's shareholders 46,735 31,457 11,311 1,550 Comprehensive income Net income 55,742 37,509 13,470 1,846 Other comprehensive income Foreign currency translation adjustment — — 3 — Total comprehensive income 55,742 37,509 13,473 1,846 Less: total comprehensive income attributable to non-controlling interest (9,007) (6,052) (2,159) (296) Total comprehensive income attributable to the Zhengye Biotechnology Holding Limited's shareholders 46,735 31,457 11,314 1,550 Earnings per share: Ordinary shares – basic and diluted 1.02 0.69 0.25 0.03 Weighted average shares outstanding used in calculating basic and diluted earnings per share: Ordinary shares – basic and diluted* 45,666,376 45,666,376 45,666,376 45,666,376 * Retroactively adjusted for effect of a 4-for-1 forward split on June 6, 2024. ZHENGYE BIOTECHNOLOGY HOLDING LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands of RMB and US$, except for number of shares) For the years ended December 31, 2022 2023 2024 RMB RMB RMB US$ CASH FLOWS FROM OPERATING ACTIVITIES Net income 55,742 37,509 13,470 1,846 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 18,800 23,912 24,163 3,310 Allowance (reversal) for credit losses 9,735 (3,714) (1,782) (244) Impairment for inventory and intangible asset 968 10,026 5,962 817 Loss on disposal of property and equipment — 187 174 24 Deferred tax expenses (benefits) (1,311) 541 924 127 Unrealized gains on short-term investments — — (209) (29) Unrealized foreign exchange gain — — (679) (93) Changes in operating assets and liabilities: Notes receivable (22,650) 8,310 (3,752) (514) Accounts receivable (24,957) 31,044 16,345 2,240 Account receivable-a related party 233 — — — Inventories (12,325) (12,902) (5,882) (806) Other receivables (4) (563) (1,283) (176) Other receivable-a related party — (738) — — Advance to suppliers (713) (619) (7,677) (1,052) Accounts payable (9,673) (35,613) (404) (56) Taxes payable 3,191 (7,702) (229) (31) Accrued expense and other liabilities 207 (582) 2,698 370 Contract liabilities 317 (715) (400) (55) Other payables – non-current (225) (197) (393) (54) Net cash provided by operating activities 17,335 48,184 41,046 5,624 CASH FLOWS FROM INVESTING ACTIVITIES Purchase of short-term investments — (1,224) — — Purchase of property, plant and equipment (27,328) (7,396) (13,587) (1,862) Prepayment for purchase of intangible assets — (4,204) (14,186) (1,943) Proceeds from disposal of property, plant and equipment — 1,059 108 15 Net cash used in investing activities (27,328) (11,765) (27,665) (3,790) CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from loans 99,852 79,860 90,122 12,347 Repayment of loans (64,972) (54,890) (92,860) (12,722) Proceeds from related parties — — 146 20 Dividend payment to shareholders (21,425) (39,452) (16,023) (2,195) Deferred IPO expenses — (4,497) (3,514) (481) Net cash provided by (used in) financing activities 13,455 (18,979) (22,129) (3,031) Net increase (decrease) in cash and restricted cash 3,462 17,440 (8,748) (1,197) Effect of exchange rate changes on cash — — 168 22 Cash and restricted cash at beginning of year 6,284 9,746 27,186 3,724 Cash and restricted cash at end of year 9,746 27,186 18,606 2,549 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid for: Interest 2,839 4,423 3,985 546 Income taxes 8,481 10,486 116 16 NON-CASH INVESTING AND FINANCING ACTIVITIES: Liabilities assumed in connection with purchase of property, plant and equipment 11,379 2,345 8,633 1,183
A12 藝術空間
biotechnology
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
